Bold claim: Even on therapy, HIV-infected cells aren’t truly dormant—they still shed viral fragments that fuel long-term inflammation and the risk of organ damage, heart issues, and a rebound if treatment lapses. This is the core issue researchers are tackling, and it just got more intriguing with a new tool that maps these hidden cellular habits.
San Francisco-based scientists report that the long-assumed “latent” HIV reservoir is more nuanced. While antiretroviral therapy (ART) blocks the creation of fresh virus, some reservoir cells keep producing viral fragments. Nadia Roan, PhD, a senior investigator at Gladstone Institutes, explains that the reservoir isn’t entirely inactive; activity persists in surprising ways, even under ART.
This persistent viral activity helps explain why people on ART still experience inflammation and related health risks, and why the reservoir’s size correlates with how quickly HIV can rebound if treatment stops or access to care is interrupted.
To push past prior limitations, Roan’s team teamed up with researchers at the San Francisco Veterans Affairs Medical Center to develop HIV-seq, a novel method for profiling rare HIV-infected cells in people living with HIV. This tool is purpose-built to detect cells actively producing HIV RNA fragments, something standard single-cell RNA sequencing often misses.
“Using HIV-seq, we recovered and examined more HIV-infected cells and observed higher levels of HIV RNA within those cells,” notes Steven Yukl, MD, a physician-scientist at the San Francisco VA and study co-author. “For the first time, we can meaningfully characterize these reservoir cells in people whose HIV is suppressed by ART.”
What the team found underscores a distinct difference between HIV-infected cells before starting ART and after long-term suppression. The pre-ART cells tended to be inflammatory and cytotoxic, with lower expression of genes that help suppress HIV, suggesting the virus could more easily replicate. Roan describes these cells as fiery, reflecting their aggressive behavior.
In contrast, reservoir cells from people on ART were calmer and anti-inflammatory, showing survival-boosting features and a reduced tendency to be killed by immune responses. Interestingly, these cells also overexpress certain proteins linked to sustained proliferation and to dampening both HIV production and immune activity.
These insights align with ongoing clinical work exploring drugs that target pathways the virus may exploit to keep its host cell alive. Yukl emphasizes that the findings support pursuing strategies to interrupt reservoir cell survival, potentially weakening the reservoir’s long-term persistence.
Roan’s team is actively testing whether interventions aimed at these pro-survival pathways can slow or halt reservoir cell multiplication in laboratory models. The researchers view HIV-seq as a springboard—a powerful tool to illuminate how the reservoir persists for decades and to guide future therapies aimed at eradicating or stabilizing it.
In short, this research reframes the HIV reservoir from a uniformly dormant pool to a spectrum of active and quiet cells, offering new avenues for treatment and a clearer understanding of how the virus hides and endures under ART. As with any scientific frontier, the implications are debated: does targeting reservoir cell survival risk unintended immune effects? Could there be a trade-off between eliminating infected cells and maintaining immune balance? Share your thoughts below: should therapies prioritize forcing reservoir cells into a detectable, targetable state, or focus on broad strategies to suppress residual viral activity? And where do you stand on the idea that a truly curable cure might require a combination of approaches addressing both viral silence and host cell survival?
